Richmond Pharmacology are pleased to announce our participation in the American Heart Association’s Hypertension Scientific Sessions 2025, held in Baltimore from 4–7 September.

Representing Richmond at Hypertension 2025:

  • Dr Jörg Täubel, Chief Executive Officer
  • James Rickard, Chief Scientific Officer

Our team will be available to discuss Richmond’s expertise in:

  • Early-phase hypertension and cardiovascular research
  • First-in-human and dose-response studies
  • Ambulatory BP monitoring and novel endpoints
  • Regulatory strategy and global trial delivery
  • Targeted recruitment and patient-centric design

 If you’re attending Hypertension 2025 and seeking a partner in hypertension clinical development, we welcome meeting requests at: info@richmondpharmacology.com

Learn more: Hypertension Programming - Professional Heart Daily | American Heart Association

 

‍

Latest news

Leadership Spotlight - Head of Pharmacovigilance

November 16, 2026
Amina Ghareeb on Building Richmond's Pharmacovigilance Expertise
Read more

Upcoming Event

JSCPT 2026

27 - 28 November 2026
Richmond Pharmacology is excited to join the JSCPT Annual Meeting 2026 in Tokyo, Japan, on 27-28 November 2026.
View event